Erythropoietin Receptor Assay Targets Red Blood Cell Development and Production State College, PA (20 April 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust preclinical testing portfolio to include a new Erythropoietin Receptor (EPOR) assay primarily used in the treatment of anemia and implicated in the development ofRead More
INDIGO Biosciences Expands Autoimmune-Focused Preclinical Testing Portfolio
Nuclear Factor of Activated T cells Assay Targets Preclinical Autoimmune and Oncology Research State College, PA (16 March 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust testing portfolio to include a new Nuclear Factor of Activate T cells (NFAT) assay used primarily for preclinical autoimmune research. ThisRead More
INDIGO Biosciences Expands Oncology-Focused Preclinical Testing Portfolio
Expansion Includes New Growth Factor Receptor and Transcription Factor Assays Targeting Preclinical Oncology Research State College, PA (5 January 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust testing portfolio to include five new assays used primarily for preclinical oncology research. These cell-based in vitro assays include fourRead More
INDIGO’s Preclinical Animal Model Platform Expands Zebrafish Offering
Expansion Meets Industry Demand for Cell-Based Preclinical Models for Cancer, Chemical, and Environmental Research State College, PA (6 October 2020) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust portfolio of in vitro animal model assays with three additional first-in-class zebrafish model systems. Previously available only as a live-model system, INDIGO’sRead More